	Cost-Effectiveness of Circulating Tumor DNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer Based on IMvigor011 Trial. JCO Oncol Pract Xue Z, Qie Y, Liang S, Li R, Shen C, Wu Z, Chen H, Lin Y, Li P, Hu H. PMID: 41886724 [PubMed - as supplied by publisher]
	Non-metastatic castration-resistant prostate cancer in the epoch of PSMA-ligand PET/CT: twilight? Ann Nucl Med Valsamaki PN, Tsakaldimis G. PMID: 41886175 [PubMed - as supplied by publisher]
	Point-of-Care Detection of Dual Methylation Genes for Rapid Bladder Cancer Diagnosis and Prognosis. Anal Chem Qiao S, Li Y, Gao Y, Li K, Qi R, Han D, Zhang C. PMID: 41885754 [PubMed - as supplied by publisher]
	Consolidation enfortumab vedotin and pembrolizumab after cisplatin induction in metastatic urothelial cancer: Outcomes of complete response and bladder preservation. J Int Med Res Chan KH, Cen P, Shu T, Canfield S, Zhao H, Gonzalez A, Rowe J, Tammisetti V, Ayoub H, Blanco A, Amsbaugh M, Tannir N. PMID: 41885091 [PubMed - indexed for MEDLINE]
	Radical cystectomy practice patterns in the Nordic countries: results from the prospective NorCys study. Scand J Urol Venhomaa T, Nikulainen I, Bobjer J, Bläckberg M, Bro L, Brandt SB, Ettala O, Fabrin K, Gudjonsson S, Haug ES, Högerman M, Hyldgaard JM, Jerlström T, Kirrander P, Koskinen I, Lam G, Leskinen MJ, Liedberg F, Livbjerg AH, Seikkula H, Skovhus K, Ströck V, Tuckus G, Virta V, Vrang ML, Jensen JB, Boström PJ. PMID: 41884949 [PubMed - indexed for MEDLINE]
	Review of the effect of atrazine on the HPG axes and steroidogenic pathways in males: relevance for testicular and prostate cancer. Front Toxicol Cooper RL, Simpkins JW, Breckenridge C. PMID: 41884656 [PubMed]
	Evaluation of efficacy in prostate cancer contouring for MR-guided radiotherapy using structured contouring training modules. Tech Innov Patient Support Radiat Oncol Fang B, Zahary Loreman H, Bayley C, Stewart C, George K, Al-Amoodi M, Jooya A, Quon H, Sia M, Lee SL. PMID: 41884629 [PubMed]
	Synergy of PET and MR imaging in the local and regional staging of bladder cancer. Ther Adv Urol Xu MC, Sandberg ML, Childs DD, Cengiz TB, Walker CH, Rais-Bahrami S. PMID: 41884183 [PubMed]
	Prognostic and clinicopathological value of the prognostic nutritional index in prostate cancer treated with androgen deprivation therapy: a systematic review and meta-analysis. Front Oncol Huang H, Hu J, Lan X, Li H, Chen J. PMID: 41883977 [PubMed]
	Actinium-225-PSMA versus lutetium-177-PSMA radioligand therapy for metastatic castration-resistant prostate cancer: results of an observational study. Front Oncol Kochetova TY, Potievskiy MB, Nekrasova LA, Krylov VV, Shegai PV, Ivanov SA, Kaprin AD. PMID: 41883973 [PubMed]
	PSMA PET-guided intensification of postprostatectomy salvage radiotherapy for prostate cancer: a systematic review and meta-analysis. Front Oncol Liu G, Shu Y, Hong J, Li Z, Yang X. PMID: 41883961 [PubMed]
	Antibody-drug conjugates in prostate cancer: current landscape and future directions. Ther Adv Med Oncol Ozay ZI, Hage Chehade C, Gebrael G, Ostrowski M, Sayegh N, Swami U, Agarwal N. PMID: 41883865 [PubMed]
	Digitally Assessed Nucleolar Size Compared to Traditional Pathologist WHO Grade Allocation in Clear Cell Renal Cell Carcinoma. Int J Surg Pathol Kuk M, Lowe A, Sangoi AR, Chan E. PMID: 41883298 [PubMed - as supplied by publisher]
	Head-to-head comparison between (18)F-FDG and (18)F-PSMA-1007 PET/CT in diagnosing recurrent and metastatic prostate cancer. J Transl Med Wang N, You J, Kong W, Zhu Y, Hong Z, Yang Y, Shi Y, Pei Z. PMID: 41882728 [PubMed - as supplied by publisher]
	In-silico study of machine learning discovers de novo lipogenesis for predicting prognosis and immunotherapy responses in kidney renal clear cell carcinoma. Biol Direct Liu D, Liu W, Han B, Ding T, Nan Y, Zhang Y, Xu H, Pan H, Li Z, Zhang W, Zhao E, Geng B, Jin C, Li X, Wang J, You B. PMID: 41882722 [PubMed - as supplied by publisher]
	Protocol for the internet-based lifestyle intervention to eradicate obese frailty in prostate cancer survivors (iLIVE) randomized controlled trial: a type I hybrid effectiveness implementation trial. BMC Cancer Demark-Wahnefried W, Rogers LQ, Zubkoff L, Pisu M, Hung A, Graff JN, Hamilton J, Dieckmann NF, Winters-Stone K. PMID: 41882641 [PubMed - as supplied by publisher]
	Metastasis-directed SBRT for oligometastatic hormone sensitive prostate cancer (METRO): protocol for a prospective randomised phase III trial, NCT04983095. BMC Cancer Söderkvist K, Zia M, Gunnlaugsson A, Josefsson A, Aksnessæther B, Li C, Thellenberg-Karlsson C, Alm D, Kudrén D, Lundin E, Moise G, Brandell JK, Kindblom J, Björnlinger K, Karlsson K, Riklund K, Westin M, Hedman M, Skorve N, Wikström P, Strandberg S, Jonsson J. PMID: 41882599 [PubMed - as supplied by publisher]
	Validation of Stockholm3 for prostate cancer detection in a swiss non-referral cohort: balancing biopsy reduction and diagnostic performance. World J Urol Mudlagk J, Minder O, Mortezavi A, Bulling B, Cornelius J, Arnold N, Roth B, Mordasini L, Giudici N. PMID: 41882382 [PubMed - indexed for MEDLINE]
	Response to correspondence regarding "The value of micro-ultrasound for prostate cancer screening: a retrospective real-world feasibility study". Prostate Cancer Prostatic Dis Wendler JJ, Bechstein J, Cash H. PMID: 41882121 [PubMed - as supplied by publisher]
	Re: Blackmur JP, Rossi SH, Kuusk T, et al. Prediction Models for Shared Decision-making by Patients with Localised Renal Masses: A Systematic Review and a Survey of Patient and Clinician Priorities. Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2026.02.008: Outcome Prediction in Localised Renal Cancer: We Need to Do Better. Eur Urol Oncol Roussel E, Amparore D, Albersen M. PMID: 41881759 [PubMed - as supplied by publisher]

Articles 1 - 20 / 177051

Page 1 of 8853



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy